Early Novavax coronavirus vaccine trial produced antibodies in all of its human volunteers

Researchers at Novavax.
(Image credit: ANDREW CABALLERO-REYNOLDS/AFP via Getty Images)

Another vaccine is showing promising results in the fight to find a COVID-19 solution.

Novavax, a Maryland-based company with $1.6 billion federal funding behind its coronavirus vaccine development, released two preliminary studies Tuesday. In one, all of its more than 130 human volunteers produced antibodies to combat the coronavirus, and in another, monkeys developed strong a resistence to the virus.

All of the humans in Novavax's trial may have some form of protection against COVID-19, but 56 of them produced a high level of antibodies without any dangerous side effects, The New York Times notes. Volunteers who had two doses of the vaccine three weeks apart, plus a booster, had the best results. Their antibodies measured approximately four times higher than those in patients who'd recovered from coronavirus, Stat News reports. Still, more than 60 percent of recipients had side effects including pain, headaches, and fatigue. Eight people had to be hospitalized, though their side effects were not life threatening and they were quickly released.

Subscribe to The Week

Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.

SUBSCRIBE & SAVE
https://cdn.mos.cms.futurecdn.net/flexiimages/jacafc5zvs1692883516.jpg

Sign up for The Week's Free Newsletters

From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.

From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.

Sign up

Novavax's vaccines are only in their first phase of study, while other developers have some in a phase three, where large amounts of people receive the vaccine. Still, John Moore, a virologist at Weill Cornell Medicine who was not involved in the studies, told the Times these were some of the most promising vaccine results he has seen yet. "This is the first one I'm looking at and saying, 'Yeah, I'd take that,'" Moore said. Angela Rasmussen, a virologist at Columbia University who was not involved in the studies, cautioned there's no guarantee of safety until a phase three trial compares people who get the vaccine with people who got a placebo. It's still essential this study receives a peer review as well.

To continue reading this article...
Continue reading this article and get limited website access each month.
Get unlimited website access, exclusive newsletters plus much more.
Cancel or pause at any time.
Already a subscriber to The Week?
Not sure which email you used for your subscription? Contact us